How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amlodipine-telmisartan-amiloride-compound-simvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Amlodipine, Telmisartan, Amiloride Compound , Simvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amlodipine, Telmisartan, Amiloride Compound , Simvastatin (Amlodipine, Telmisartan, Amiloride Compound , Simvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassi

marketed Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassium-sparing diuretic + statin) L-type calcium channels, AT1 angiotensin II receptor, epithelial sodium channels (ENaC), HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine, Telmisartan, Amiloride Compound , Simvastatin (Amlodipine, Telmisartan, Amiloride Compound , Simvastatin) — Chinese Academy of Medical Sciences, Fuwai Hospital. This fixed-dose combination reduces blood pressure and cardiovascular risk through calcium channel blockade, angiotensin II receptor antagonism, potassium-sparing diuresis, and cholesterol lowering.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amlodipine, Telmisartan, Amiloride Compound , Simvastatin TARGET	Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassium-sparing diuretic + statin)	L-type calcium channels, AT1 angiotensin II receptor, epithelial sodium channels (ENaC), HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassium-sparing diuretic + statin) class)

Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine, Telmisartan, Amiloride Compound , Simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-telmisartan-amiloride-compound-simvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab